SELLAS Life Sciences SLS Stock
SELLAS Life Sciences Price Chart
SELLAS Life Sciences SLS Financial and Trading Overview
| SELLAS Life Sciences stock price | 1.16 USD |
| Previous Close | 1.66 USD |
| Open | 1.67 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 1000 |
| Day's Range | 1.62 - 1.7 USD |
| 52 Week Range | 1.17 - 5.58 USD |
| Volume | 138.3K USD |
| Avg. Volume | 221.22K USD |
| Market Cap | 47.06M USD |
| Beta (5Y Monthly) | 2.250704 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.67 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6 USD |
SLS Valuation Measures
| Enterprise Value | 24M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.66 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | Infinity |
| Price/Book (mrq) | 3.5698924 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
SELLAS Life Sciences Stock Price History
| Beta (5Y Monthly) | 2.250704 |
| 52-Week Change | -27.51% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.58 USD |
| 52 Week Low | 1.17 USD |
| 50-Day Moving Average | 1.6 USD |
| 200-Day Moving Average | 2.37 USD |
SLS Share Statistics
| Avg. Volume (3 month) | 221.22K USD |
| Avg. Daily Volume (10-Days) | 117.14K USD |
| Shares Outstanding | 28.35M |
| Float | 26.47M |
| Short Ratio | 6.42 |
| % Held by Insiders | 0.37% |
| % Held by Institutions | 7.82% |
| Shares Short | 1.19M |
| Short % of Float | 4.20% |
| Short % of Shares Outstanding | 4.20% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:50 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -90.26% |
| Return on Equity (ttm) | -414.72% |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 900K USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -35654000 USD |
| Diluted EPS (ttm) | -1.56 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 23.9M USD |
| Total Cash Per Share (mrq) | 0.84 USD |
| Total Debt (mrq) | 849K USD |
| Total Debt/Equity (mrq) | 6.45 USD |
| Current Ratio (mrq) | 1.678 |
| Book Value Per Share (mrq) | 0.465 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -28786000 USD |
| Levered Free Cash Flow (ttm) | -19222000 USD |
Profile of SELLAS Life Sciences
| Country | United States |
| State | NY |
| City | New York |
| Address | Times Square Tower |
| ZIP | 10036 |
| Phone | 646 200 5278 |
| Website | https://www.sellaslifesciences.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 17 |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.
Q&A For SELLAS Life Sciences Stock
What is a current SLS stock price?
SELLAS Life Sciences SLS stock price today per share is 1.16 USD.
How to purchase SELLAS Life Sciences stock?
You can buy SLS shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for SELLAS Life Sciences?
The stock symbol or ticker of SELLAS Life Sciences is SLS.
Which industry does the SELLAS Life Sciences company belong to?
The SELLAS Life Sciences industry is Biotechnology.
How many shares does SELLAS Life Sciences have in circulation?
The max supply of SELLAS Life Sciences shares is 78.58M.
What is SELLAS Life Sciences Price to Earnings Ratio (PE Ratio)?
SELLAS Life Sciences PE Ratio is now.
What was SELLAS Life Sciences earnings per share over the trailing 12 months (TTM)?
SELLAS Life Sciences EPS is -0.67 USD over the trailing 12 months.
Which sector does the SELLAS Life Sciences company belong to?
The SELLAS Life Sciences sector is Healthcare.
SELLAS Life Sciences SLS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 18350.19 USD — |
-2.64
|
7.23B USD — | 18216.63 USD — | 18992.3 USD — | — - | 7.23B USD — |
| NASDAQ Capital Market Composite RCMP | 102.02 USD — |
-3.29
|
— — | 101.66 USD — | 107.21 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 993.66 USD — |
-1.66
|
— — | 990.15 USD — | 1016.8 USD — | — - | — — |
- {{ link.label }} {{link}}